Business
Oncolytics Biotech® Announces Proposed Public Offering
Oncolytics Biotech® Announces Proposed Public Offering Canada NewsWire CALG...
About this update from Oncolytics Biotech Inc.
[{"type":"text","content":"\n\n\n\nOncolytics Biotech® Announces Proposed Public Offering\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\n\nCanada NewsWire\nCALGARY, May 23, 2017\n\n\n\nCALGARY, May 23, 2017 /CNW/ - Oncolytics Biotech® Inc. (Oncolytics or the Company) (TSX:ONC) (OTCQX:ONCYF) today announced that it will undertake a public offering (the \"Offering\") of securities of the Company (\"Securities\"). The Offering will be effected pursuant to a prospectus supplement (the \"Prospectus Supplement\") to the Company's base shelf prospectus dated February 16, 2016 (together with the Prospectus Supplement, the \"Prospectus\"), to be filed with securities regulators in each of the Provinces of Canada, other than Quebec. The Securities may also be offered for sale in the United States pursuant to exemptions from the registration requirements of the U.S. Securities Act and applicable state laws. The number of Securities to be distributed, the price and other terms of the Offering will be determined in the context of the market with final terms to be determined at the time of pricing.   \n\nThe Offering is subject to a number of conditions, including, without limitation, receipt of approval of the Toronto Stock Exchange.  Oncolytics expects to use the net proceeds from the offering for working capital, expanding partnering activities and advancing the clinical program for metastatic breast cancer.\n\nCanaccord Genuity is acting as sole bookrunner and sole lead for the Offering. \n\nA preliminary prospectus supplement and accompanying prospectus describing the terms of the proposed offering will be filed with on SEDAR. Copies of the preliminary prospectus supplement and accompanying prospectus relating to the offering may be obtained, when available, from Canaccord Genuity, Attention: Syndication - Canaccord Genuity Corp., P.O. Box 516, 161 Bay Street, Suite 3000, Toronto, ON, M5J 2S1. Electronic copies of the preliminary prospectus supplement and accompanying prospectus will also be available on SEDAR at www.sedar.com.\n\nAbout Oncolytics Biotech Inc.Oncolytics is a ...